SCHEMBL4244043

SCHEMBL4244043

C1=CC2CC1CC2CNC1CCc2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.49
MAOB P27338 4/20 0.49
BCHE P06276 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
ACHE P22303 1/20 0.49
ADRA1A P35348 1/20 0.49
HTR6 P50406 1/20 0.49
PDPK1 O15530 1/20 0.45
KDM1A O60341 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
SLC18A3 Q16572 1/20 0.38
KDM4E B2RXH2 2/20 0.37
TSHR P16473 1/20 0.37
FADS1 O60427 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23330224 0.70 MAOA (0.64) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL6851081 0.70 MAOA (0.68) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL6851796 0.70 MAOA (0.68) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL9499569 0.70 MAOA (0.63) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL10282640 0.70 MAOA (0.68) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL2465734 0.69 MAOA (0.71) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL4258764 0.68 SRD5A1 (0.40) MAOAMAOBPDPK1KDM1A
Hydrochloric Acid SCHEMBL5970523 0.68 MAOA (0.69) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL13911216 0.67 MAOA (0.64) MAOAMAOBBCHEADRA2BADRA2C
SCHEMBL24575404 0.67 KDM4E (0.48) KDM4ETSHRALDH1A1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PEDREGAL-TERCERO CONCEPCION 2009-01-22 US disclosed
US-7399774-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2008-07-15 US disclosed
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists OPRM1, OPRL1, OPRK1 MAOA 303/4885MAOB 200/4885BCHE 2294/4885
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRK1, OPRD1 MAOA 388/4885MAOB 255/4885BCHE 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.